Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login